Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Moneo: Avelumab plus chemotherapy in peri-operative treatment for resectable gastric or gastroesophageal junction cancer
2024-516777-77-00Phase 2Authorised
- Sponsor
- Vall d'Hebron Institute of Oncology
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of avelumab in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Vall d'Hebron Institute of Oncology. Primary endpoint: Pathological complete response (pCR) rate. Planned start Oct 2024; status: authorised.
02
Drugs
avelumab
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2024-516777-77-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516777-77-00.